ALTO-207 in Adults With Treatment-resistant Depression (TRD)
Recruiting
Phase 2
Interventional Study
Treatment-resistant Depression (TRD)
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 178 (estimated)
- Sponsor
- Alto Neuroscience · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Male and female participants, ages 18 to 75 years, inclusive, at the time of signing the ICF.
* Prior diagnosis of MDD without psychotic symptoms (in the current episode) and have confirmatory diagnosis of current MDD (moderate to severe).
* Failure to respond (\<50% improveme…
Contacts